8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
May 11, 2026·SEC
AnaptysBio, Inc.(ANAB)Earnings, Financials & Key Ratios
ANAB•NASDAQ
$67.33
Price updated Jul 7, 2026
AboutAnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Show more
- Revenue$235M+157.0%
- EBITDA$50M+144.7%
- Net Income-$13M+90.9%
- EPS (Diluted)-0.46+91.0%
- Gross Margin98.97%+224.5%
- EBITDA Margin21.45%+117.4%
- Operating Margin20.42%+116.2%
- Net Margin-5.64%+96.5%
- ROE-24.49%+86.6%
ANAB Price & Volume
AnaptysBio, Inc. (ANAB) stock price & volume — 10-year historical chart
Loading chart...
Lumpy Milestone Revenue Masks Structural Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Strained
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Pipeline Execution Risk
Key Thesis Takeaways
- AnaptysBio's reliance on sporadic milestone payments creates significant volatility in financial performance, as evidenced by the 8% revenue decline in 2026Q1.
- While the GSK partnership provides a critical cash floor, the company's persistent negative retained earnings of $825.4 million and high R&D spend exceeding $30 million per quarter underscore the substantial execution risk inherent in its clinical pipeline.
- Investors should monitor the sustainability of royalty streams and the company's ability to manage its debt-to-equity ratio, which spiked to 21.76 in 2026Q1.
Verdict Logic
the company's reliance on non-recurring milestone payments to fund operations, combined with a debt-to-equity ratio of 21.76, suggests significant long-term solvency risks that outweigh current liquidity buffers.
ANAB Growth Metrics
AnaptysBio, Inc. (ANAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years29.58%
5 Years25.62%
3 Years183.58%
TTM107.73%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM80.95%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM77.96%
Return on Capital
10 Years-14.53%
5 Years-15.48%
3 Years-15.77%
Last Year12.54%
ANAB Recent Earnings
AnaptysBio, Inc. (ANAB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$1.84-475.0%
$0.32
Rev
$26M+35.5%
$19M
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$1.58+77.5%
$0.89
Rev
$108M+24.4%
$87M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.52+149.1%
$1.06
Rev
$76M+248.2%
$22M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.34+10.7%
$1.50
Rev
$22M+90.5%
$12M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $1.84vs $0.32-475.0% | $26Mvs $19M+35.5% |
| Q2 2026 | Mar 3, 2026 | $1.58vs $0.89+77.5% | $108Mvs $87M+24.4% |
| Q4 2025 | Nov 4, 2025 | $0.52vs $1.06+149.1% | $76Mvs $22M+248.2% |
| Q3 2025 | Aug 7, 2025 | $1.34vs $1.50+10.7% | $22Mvs $12M+90.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for AnaptysBio, Inc. (ANAB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $67.33 | $2.9B | -146.36 | 157.01% | -5.64% | -24.49% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $27.67 | $3.46B | -212.85 | 91.34% | -0.57% | -1.41% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — |
Compare ANAB vs Peers
AnaptysBio, Inc. (ANAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANAB SEC Filings & Documents
AnaptysBio, Inc. (ANAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ANAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANAB Frequently Asked Questions
AnaptysBio, Inc. (ANAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is AnaptysBio, Inc.'s revenue?
AnaptysBio, Inc. (ANAB) reported $232.4M in revenue for fiscal year 2025. This represents a 4138% increase from $5.5M in 2013.
How fast is AnaptysBio, Inc. growing?
AnaptysBio, Inc. (ANAB) grew revenue by 157.0% over the past year. This is strong growth.
Is ANAB profitable?
AnaptysBio, Inc. (ANAB) reported a net loss of $26.8M for fiscal year 2025.
Dividend & Returns
What is ANAB's return on equity?
AnaptysBio, Inc. (ANAB) has a return on equity (ROE) of -24.5%. Negative ROE indicates the company is unprofitable.
What is AnaptysBio, Inc.'s free cash flow?
AnaptysBio, Inc. (ANAB) generated $4.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.